REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

Mon 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250818:nRSR7663Va&default-theme=true

RNS Number : 7663V  AstraZeneca PLC  18 August 2025

18 August 2025

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announces that, on 15 August 2025, it was
notified of a transaction in the Company's ordinary shares of $0.25 each
(Ordinary Shares), by Aradhana Sarin, Executive Director and Chief Financial
Officer, on 14 August 2025, as set out below.

 

 

 PDMR            Position                                        Nature of the transaction    Quantity    Price per Ordinary Share
 Aradhana Sarin  Executive Director and Chief Financial Officer  Sale of Ordinary Shares      9563        £115.117

 

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Aradhana Sarin

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification/Amendment                               Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4i   Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary Shares of US$0.25 each in AstraZeneca PLC

      Identification code                                          GB0009895292

 b)   Nature of the transaction                                    Sale of Ordinary Shares of US$0.25 each in AstraZeneca PLC

 c)   Price(s) and volume(s)

Price(s)   Volume(s)
                                                                   £115.117   9563
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      14 August 2025

 f)   Place of the transaction                                     LON

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

14 August 2025

f)

 

Place of the transaction

 

LON

 

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
 

 

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUWVURVKUWAAR